A biotechnology company focused on the discovery, development and commercialization of novel therapeutics that harness the immune system to fight cancer.
BATS data provided in real-time. NYSE, NASDAQ and NYSEMKT data delayed 15 minutes.
Real-Time prices provided by BATS. Market data provided by Interactive Data.
Company fundamental data provided by Morningstar. Earnings Estimates, Analyst Ratings and Key Statistics provided by Zacks.
SEC Filings and Insider Transactions provided by Edgar Online.
Powered and implemented by Interactive Data Managed Solutions. Terms & Conditions
RSS Headlines
Fool UK
Recs
As a Medical Oncologist, I will be Dendreon's primary customer. Right now, I have many reservations about Provenge including price (the old guys I take care of mostly lose interest when I tell them it will cost $93,000), access, (it will only be available in major markets), and toxicity (usually higher in the real (non academic) world. Taxotere (Provenge's main competition) will be generic soon, and several other promising prostate cancer drugs are in the near term pipeline.
As of 7/17/2010, my member rating is 95.94. Much of that is attributable to my Dendreon Provenge pick, originated on 12/11/06 at $4.36 cents.As Dendreon's primary customer, it sounds like you have a lot to lose by the paradigm changing cancer treatment called Provenge. Provenge will be covered by Medicare! Access:give it 2 to 3 years and Dendreon's Intellivenge distribution system and factory capacity will come online to increase supply to meet the overwhelming demand.Toxicity: Taxotere (chemo - going off patent and will now be generic): Current scenario: I take Taxotere for 6-9 months, lose my hair, lose my nails, am constantly nauseated, throw up, get rushed to the hospital and end up paying much more than Provenge's $93,000. due to the side effects of Taxotere. My life is generally misable and then I die.Provenge (newly FDA approved therapeutic vaccine - on patent): I take 3 courses of Provenge over a period of about 6 weeks and then I'm done!
JDR524:
What do you think now? CMS recommended reimbursement. Any update to your original statement?
CMS had no choice. But J & J's Abiraterone (Zytiga) was just approved. It is a pill that lowers intracellular testosterone. Response rates are reasonable and medication is tolerable. Patients can get it at any pharmacy instead of travelling to specialized Provenge infusion center. My prediction is most oncologists will use it before Provenge. Also, I spoke recently with medical oncologist involved with Provenge trials and in his opinion, only pts with minimal metastatic disease really benefitted. I expect the first set of patients getting Provenge will be very advanced and have dissappointing results. This could have a negative impact on prescribing. Remember, Provenge now has its toughest ahead...The Real World. I have three patients getting Provenge right now, and one on Zytiga...stay tuned...jdr...
JDR524 1, binarybit1 0
JDR524 , " I have three patients getting Provenge right now, and one on Zytiga...stay tuned...jdr..." Submitted: 5/27/2011 10:46:12 PM
Do u have an update? Thanks
Wow. It's been almost 2 years since I've posted. I'm going to do a chart review soon on the approximately dozen men or more I've treated. Honestly I'm not sure the drug helps at all. I'm patiently awaiting post approval data or something from a prostate cancer thought leader who isn't on dndn payroll. My rep offered to bring someone to the practice--now my rep is gone ??? Given the FDA approval and the safety--I'm giving it when indicated-- but I'm making it very clear to pts that I'm not sure it helps. It's a low risk---very high cost intervention. I'll post further after I've analyzed my data more fully. @jdr524 if interested.